Docetaxel: a review of its use in metastatic breast cancer.
about
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerNew modalities of cancer treatment for NSCLC: focus on immunotherapyA kernelisation approach for multiple d-Hitting Set and its application in optimal multi-drug therapeutic combinationsVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapySpiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identificationGene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerChemosensitization of cancer cells by siRNA using targeted nanogel delivery.Docetaxel-induced photolichenoid eruption.Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.A spatial model of tumor-host interaction: application of chemotherapy.Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin.Prostate cancer: current treatment and prevention strategies.Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents.Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings.Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxelInhibition of paclitaxel-induced decreases in calcium signaling.The role of genetic variability in drug metabolism pathways in breast cancer prognosis.Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or DocetaxelInduction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis.Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different MechanismsPharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaA biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice.Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma.Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenograftsFOXM1 and its oncogenic signaling in pancreatic cancer pathogenesisLevel of evidence for therapeutic drug monitoring of taxanes.Docetaxel nanotechnology in anticancer therapy.Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategiesThe role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatmentNon-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Role of delta-like ligand-4 in chemoresistance against docetaxel in MCF-7 cells.Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes.Amorphous calcium silicate hydrate/block copolymer hybrid nanoparticles: synthesis and application as drug carriers.Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status.
P2860
Q26795509-21295EBB-4F43-4925-96B8-AAE253CC5C20Q26829161-D9E65B9E-5892-4E19-BD25-6B4556C9A0A7Q28475822-05A5CA5F-5909-46BD-8EC7-1E5E35604ED0Q28477876-1CBD65CA-1089-4264-B72F-8DF3FD44F038Q28828506-B3297F9C-EA1C-43EB-A771-68BCBFC31F8BQ30484735-0D14B20A-BEAF-4D5A-BFC1-D5EB3E8267FCQ33523195-8F51BF40-DF3C-494B-BC53-4C9CB1943208Q33874080-2C18E34D-DCA6-44E7-9D60-E24EF92FEA03Q33947252-338B4FFD-4AF4-4686-8243-446ECB80F8AFQ34309868-F66E540C-4961-4A44-9D98-A96F51357201Q34353491-D3880509-9B60-41D2-B203-E688D6B20E73Q34374546-7021F7CF-3A93-4DE6-B6AB-4F0093625701Q34556212-BD6F31E9-BC5E-4698-AFB5-9699E05A72EBQ34721483-F1E28A51-BF44-4ADF-A240-AC58626B23B9Q34728078-EA2E47AF-8C05-49D7-852F-F9E946967171Q35064955-FA353CB2-B241-4D0A-B714-9D8A5DACAFB6Q36350991-16745A64-E659-433A-AA7F-E8ECB198EA07Q36368235-EA3075A1-ADDA-40A9-B4A3-5E13842ED301Q36497088-844FD6B4-BFD8-4CF2-B6C8-F1E94BB82572Q36520778-1884F84C-F931-422D-8EB0-958F66C12D19Q36652542-E3D8FE9D-F72C-43E9-8393-7FB65024053AQ36815168-C6A8C765-F626-4E43-9477-2D25E5C17021Q36832200-C260883B-D541-4280-9543-AED3C3C00130Q37170005-54431191-4F97-4091-8E9B-0002B10339DDQ37331739-D8FFE557-A68F-42CE-99BF-FE02565B1DE2Q37461274-E0A45825-CC59-4974-8BFA-629D715C161FQ37705923-AE146CBD-49F5-4D35-9CFC-9D13BEF1032BQ37716906-7A9F2BAE-3FDB-4A34-969B-A621D566CFE1Q37788732-7F411839-70DA-4A04-BAE2-AFB8B0B19227Q38003964-709AF261-1168-4AFB-8CD0-D57BC1440522Q38088759-FFA1E324-5C7F-4849-BF11-85C93E721F80Q38113988-F702C635-481B-47F5-BF57-15F45661FBCFQ38161363-7D68D4CA-B693-4CAB-8049-05B1DCA8056BQ38226821-B23E697B-891A-4C2C-A7A4-66E8C6F1B987Q38373911-09E38FFE-EF0F-461D-9675-F23D6D2AED43Q38546598-7F3583C0-3C6F-4A08-83BA-D5CB64A7DDFEQ38762728-9B08C716-B2F0-4903-8A64-2FC16EA28BB3Q38893881-DD572CD4-4005-4646-8CED-44B9EFBA7AB4Q39178323-942CE2FE-2CEA-4CDD-8657-1FD22F23D35AQ39580347-CBFCAF38-459E-4A4D-AAA4-9BC95711E424
P2860
Docetaxel: a review of its use in metastatic breast cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Docetaxel: a review of its use in metastatic breast cancer.
@ast
Docetaxel: a review of its use in metastatic breast cancer.
@en
Docetaxel: a review of its use in metastatic breast cancer.
@nl
type
label
Docetaxel: a review of its use in metastatic breast cancer.
@ast
Docetaxel: a review of its use in metastatic breast cancer.
@en
Docetaxel: a review of its use in metastatic breast cancer.
@nl
altLabel
Docetaxel
@en
prefLabel
Docetaxel: a review of its use in metastatic breast cancer.
@ast
Docetaxel: a review of its use in metastatic breast cancer.
@en
Docetaxel: a review of its use in metastatic breast cancer.
@nl
P1433
P1476
Docetaxel: a review of its use in metastatic breast cancer.
@en
P2093
Caroline Fenton
P304
P356
10.2165/00003495-200565170-00007
P577
2005-01-01T00:00:00Z
P6179
1046742664